Drug Trial Radar · NCT05502341
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
689
Actual
Start
Aug 16, 2022
Primary completion
Sep 29, 2025
Study completion Dec 2029
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Conditions
- HIV-1-infection
Interventions
BictegravirDrug
Tablets administered orally without regard to food
LenacapavirDrug
Tablets administered orally without regard to food
BIC/LEN FDCDrug
Tablets administered orally without regard to food
Stable Baseline RegimenDrug
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva). * Nucleos(t)ide Reverse Transcriptase Inhibitors: * Abacavir * Emtricitabine * Lamivudine * Tenofovir alafenamide * Tenofovir disoproxil fumarate * Zidovudine * Non-Nucleosite Reverse Transcriptase Inhibitors: * Delavirdine * Efavirenz * Nevirapine * Rilpivirine * Doravirine * Integrase Inhibitors: * Bictegravir * Cabotegravir * Dolutegravir * Elvitegravir * Raltegravir * Protease Inhibitors: * Atazanavir * Darunavir * Fosamprenavir * Indinavir * Lopinavir * Nelfinavir * Saquinavir * Tipranavir * Chemokine Co-receptor 5 (CCR5) Antagonist: * Maraviroc * Fusion Inhibitors: * Enfuvirtide * gp120 Attachment Inhibitor: * Fostemsavir * Anti-CD4 Monoclonal Antibodies: * Ibalizumab-uiyk
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot AlgorithmTime frame: Week 24
- Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmTime frame: Week 48
Locations
94 sites in 15 countries. Site status is shown where the registry gives one.
Be Well Medical Center
Berkeley, California
Pacific Oaks Medical Group
Beverly Hills, California
Ruane Clinical Research Group, Inc
Los Angeles, California
Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
Oakland, California
Bios Clinical Research
Palm Springs, California
University of California San Diego (UCSD)
San Diego, California
Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
Torrance, California
The Men's Health Foundation
West Hollywood, California
Denver Health Medical Center
Denver, Colorado
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut
Midland Florida Clinical Research Center, LLC
DeLand, Florida
Therafirst Medical Centers
Fort Lauderdale, Florida
Gary Richmond, MD, PA, Inc.
Fort Lauderdale, Florida
Midway Immunology & Research Center, LLC
Ft. Pierce, Florida
Schiff Center for liver Diseases/University of Miami
Miami, Florida
Floridian Clinical Research
Miami Lakes, Florida
Orlando Immunology Center
Orlando, Florida
Therapeutic Concepts, PA
Orlando, Florida
Triple O Research Institute PA
West Palm Beach, Florida
Atlanta ID Group
Atlanta, Georgia
Mercer University School of Medicine
Macon, Georgia
Howard Brown Health Center
Chicago, Illinois
Kansas City Care Clinic
Kansas City, Missouri
Southampton Healthcare, Inc.
St Louis, Missouri
Saint Michael's Medical Center
Newark, New Jersey
AXCES Research Group
Santa Fe, New Mexico
New York Presbyterian Hospital
Flushing, New York
Ricky K. Hsu, MD, PC
New York, New York
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina
East Carolina University
Greenville, North Carolina
Philadelphia FIGHT
Philadelphia, Pennsylvania
Medical University of South Carolina (MUSC) Research NEXUS
Charleston, South Carolina
Central Texas Clinical Research
Austin, Texas
St. Hope Foundation
Bellaire, Texas
AIDS Arms, Inc., DBA Prism Health North Texas
Dallas, Texas
North Texas Infectious Diseases Consultants
Dallas, Texas
Texas Centers for Infectious Disease Associates
Fort Worth, Texas
Gordon E. Crofoot MD PA
Houston, Texas
Diagnostic Clinic of Longview - Center for Clinical Research
Longview, Texas
Peter Shalit, MD
Seattle, Washington
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.